Müller glia can serve as a source for retinal regeneration in some non-mammalian 9 vertebrates. Recently we found that this process can be induced in mouse Müller glia after 10 injury, by combining transgenic expression of the proneural transcription factor Ascl1 and the 11 HDAC inhibitor TSA. However, new neurons are only generated from a subset of Müller glia in 12 this model, and identifying factors that limit Ascl1-mediated MG reprogramming could potentially 13 make this process more efficient, and potentially useful clinically. One factor that limits 14 neurogenesis in some non-mammalian vertebrates is the STAT pathway activation that occurs 15 in Müller glia in response to injury. In this report, we tested whether injury induced STAT 16 activation hampers the ability of Ascl1 to reprogram Müller glia into retinal neurons. Using a 17 STAT inhibitor, in combination with our previously described reprogramming paradigm, we 18 found a large increase in the ability of Müller glia to generate neurons, similar to those we 19 described previously. Single-cell RNA-seq showed that the progenitor-like cells derived from 20 Ascl1-expressing Müller glia have a higher level of STAT signaling than those that become 21 neurons. Using Ascl1 ChIP-seq and DNase-seq, we found that developmentally inappropriate 22 Ascl1 binding sites (that were unique to the overexpression context) had enrichment for the 23 STAT binding motif. This study provides evidence that STAT pathway activation reduces the 24 efficiency of Ascl1-mediated reprogramming in Müller glia, potentially by directing Ascl1 to 25 inappropriate targets. 26 27 28 29 Functional regeneration of retinal neurons occurs naturally in teleost fish and many 32 amphibians 1-6 . In zebrafish, the Müller glia (MG) respond to a variety of injury models by 33 generating cells that resemble multipotent progenitor cells found in the developing retina. These 34 MG-derived progenitors have the capacity to produce all types of retinal neurons and restore 35 visual function 7 . In amphibians and embryonic birds, the pigmented epithelial cells undergo a 36 similar transition to retinal progenitor cells, and can regenerate a new, laminated retina 8,9 .
( Figure 3A ), differentially associated with the different treatment conditions ( Figure 3C ). We 158 identified the cell types comprising the clusters by their unique expression of specific known 159 marker genes. Some of these genes are shown projected onto the individual clusters ( Figure   160 3B) and additional genes are shown associated with the clusters as a heatmap ( Figure 3F ). For 161 example, Clusters 3 and 4 were comprised of cells almost exclusively from the untreated (WT) 162 condition and expressed genes normally present in MG, such as Glul and Aqp4; these were 163 classified as "MG" clusters ( Figure 3D ). Clusters 0 and 2 showed enrichment for progenitor 164 genes (Dll1; Figure 3B ) but lacked neuronal gene expression (Otx2 and Cabp5) and showed 165 reduced glial gene expression (Glul). We therefore classified clusters 0 and 2 as "Progenitor-166 like" cells. Clusters 1 and 6 showed enrichment for neuronal genes and greatly reduced 167 expression of glial genes and were classified as "MG-derived Neurons". In addition to these 168 major clusters, there were two contaminating cell populations that we do not think were derived 169 from MG. These include microglial cells, identified by their expression of Aif1 (IBA1), and a 170 small number of cells that express Rho and other photoreceptor genes that we consider 
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The immunofluorescent analysis of retinas from the ANTSi condition indicated that a 176 greater percentage of progenitor-like cells differentiate into neurons when compared with the 177 ANT treatment. We analyzed the scRNA-seq results to determine whether a similar trend could 178 be detected. Quantifying the number of WT, ANT, and ANTSi cells in the MG, progenitor-like, 179 or MG-derived neuron clusters ( Figure 3E ) revealed nearly double the number of MG-derived 180 neurons in the ANTSi treatment compared to ANT (29% of total ANTSi cells vs. 16% of total 181 ANT cells). The increase in the MG-derived neuron population in the ANTSi treatment was 182 accompanied by a decrease in the number of progenitor-like cells. These data support the immunofluorescent analysis that STAT inhibition results in a population shift of MG from 184 progenitor-like cells to MG-derived neurons and doubles reprogramming efficacy.
185
To better understand the trajectory of the reprogramming process, we used the Monocle 186 analysis package on a subset of the data that only included MG, progenitor-like cells, and MG-187 derived neurons from clusters 0, 1, 2, 3, 4, and 6 ( Figure 4A ). We found the pseudotime scale 188 tracked with our classified cell types, with MG being the root state and transitioning through the 189 progenitor-like cell state and eventually progressing towards MG-derived neurons ( Figure 4B ).
190
We observed cells decreasing expression of glial genes (e.g. Glul) as they progress towards 
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Although the trajectory analysis shows that MG progress to neurons through a 195 progenitor-like state, it also suggests that this state is not identical in the ANT and ANTSi 196 conditions. The progenitor-like cells in these two conditions cluster separately and although both 197 clusters express progenitor genes, like Dll1, the pseudotime plot suggests ANT reprogrammed 198 cells are "closer" to MG than the cells from the ANTSi treated retinas. This led us to hypothesize 199 that progenitor cells may be kept in a stable, but non-neural state, by STAT pathway activation.
200
Indeed, the progenitor-like cells highly express various STAT pathway target genes (e.g. Gfap,
201
Id1, Id3, Socs3, Figure 3F 
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DNase Track) 29 . We compared the retinal Ascl1 peaks to previous ChIP-seq for Ascl1 in other 212 neural tissues. For this analysis, we focused on the highest scoring peaks that replicated in two 213 independent P0 retinal Ascl1-ChIP-seq runs (7587 sites, Figure 5A ). When the three-different 214 neural Ascl1-ChIP-seq datasets were compared, we found that the majority of the Ascl1-bound 215 regions in each type of neural tissue were unique to that tissue ( Figure 5B ); for the peaks 216 present in retina and another neural tissue, there was approximately the same degree of 217 overlap for each of the combinations, while only a relatively small subset of peaks were 218 common to all neural tissues (764; Figure 5A -B; Core Ascl1 track). Gene Ontology analysis 219 using the GREAT algorithm 30 showed that those peaks unique to retina were enriched for eye, 220 optic and retinal GO terms (for mouse phenotype), while those regions common to all three 221 neural tissues instead have enrichment for GO terms of non-retinal neural tissues (e.g. 222 telencephalon; Figure 5B ). In addition, the genes associated with these GO terms for the retinal-223 specific regions were genes expressed more highly in retina than in other regions of the CNS, 224 like cerebral cortex or spinal cord (e.g. Rax, Six3, Atoh7, Otx2; Figure 5B ), while those genes 225 associated with the Ascl1-bound regions common to all three neural tissues were potentially 226 representative of a more generic neural program of differentiation (Notch1, Insm1, and Dll1), 227 though it is important to note that there are also region-specific regulatory sites for common 228 targets, like Hes5 and Sox2.
229
To determine the extent to which Ascl1 binds to similar regions in MG as in retinal 230 progenitors, we performed ChIP-seq for Ascl1 in MG during the reprogramming process.
231
Retinas from P12 mice (germline-rtTA: tetO-Ascl1) were dissociated and the MG were grown in 232 culture. After 7 days, Ascl1 expression was induced in the purified MG by addition of 233 doxycycline to the culture medium. Chromatin was then collected after 6 days post-Ascl1 234 induction and subsequently processed for Ascl1 ChIP-seq. The subsequent sequencing reads were filtered and mapped to the mouse genome ( Figure 5C ) and peaks called using HOMER. In 236 total, 47,507 peaks were called with a False Discovery Rate (FDR) of 0.1%; MEME analysis 237 shows that the top-scoring motif was the canonical Ascl1 E-Box, similar to that described above 238 for the P0 retina ( Figure S2A ).
239
We performed a binding site overlap analysis between the peaks from the two cell 240 populations. As shown in Figure 5E 
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between one fifth and one quarter of the Ascl1-bound sites in MG were "pioneered" by Ascl1, 271 consistent with prior results in other cells 33 . We hypothesized that these pioneer Ascl1 binding 272 events in MG were actually occurring at regions of DNase-hypersensitivity in the P0 retina. This 273 scenario would be productive towards the goal of reprogramming the cis-regulatory landscape 274 of MG towards that of retinal progenitors. Therefore, we quantified the overlap between pioneer 275 Ascl1 binding sites in MG and P0 DNase-hotspots ( Figure 5D ). We found that 34%
276
(3591/10,575) of the pioneered sites overlap a P0 DNase-Hotspot. However, a much greater 277 number, 66% (6984/10,575) of the pioneered sites, do not overlap a DNase-Hotspot in either P0 278 retina or MG, and thus are potentially non-productive pioneered sites.
279
The preceding analysis suggests that while a third of Ascl1 pioneering events are 280 productive for reprogramming towards a retinal progenitor state, a majority of pioneering events 281 appear to be unproductive towards reprogramming to the retinal progenitor state. We 282 hypothesized that other transcription factors present in the MG might be collaborating with Ascl1 283 to direct it to these inappropriate sites 32 . To determine which factors might be associated with 284 the inappropriate Ascl1 ChIP-seq peaks in MG (i.e. not present in progenitors), we used 285 HOMER to identify sequence motifs enriched in these regions (for genes that increase >0.75 286 fold in reprogrammed MG, over P0 progenitors from our previous microarray 34 ). We found that Ascl1 was the top site followed by a generic homeodomain motif, but these regions were also 288 significantly enriched for the STAT consensus site ( Figure 5E ). Thus, the activation of the STAT 289 pathway in the MG after retinal injury may direct Ascl1 to inappropriate sites on the DNA and 290 thereby reduce its ability to reprogram MG more fully to progenitors/neurons. Figure 5F ). Additionally, a previously generated STAT3 ChIP-seq dataset 300 from oligodendrocytes in the brain (GEO: GSM2650746) indicated STAT3 binding sites in the 301 same region as the Ascl1 binding sites (STAT ChIP track, Figure 5F ). Taken together, these 302 findings suggest that STAT pathway activation and/or Ascl1 binding may induce Id gene 303 expression, which inhibits Ascl1 from initiating neurogenesis in a subset of MG.
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ChIP-seq for Ascl1 in control and STATi-treated reprogrammed Müller glia.
306
To directly assess the effect that STAT pathway activation has on Ascl1 binding at Id 307 genes and more broadly across the genome during MG reprogramming, we performed an Ascl1 308 ChIP-seq on control and STATi-treated MG. Frozen stocks of MG from P12 germline-rtTA: tetO-309 Ascl1 mice were thawed and cultured to confluency for 2 days in high FBS growth media 310 ( Figure 6A ). Cells were then given a low FBS media with STATi or vehicle for the remaining 4 311 DIV. At 3 DIV (1 day after STATi), doxycyline was administered to induce Ascl1 overexpression in the MG. Cells were then collected and fixed for ChIP-seq after 6 DIV. FASTQ files were 313 aligned to the mm10 genome using Bowtie2 and peaks were called using MACS2.
314
Representative tracks show Ascl1 Chip-seq for the Ascl1 expressing MG and sister cells treated 315 with STATi are shown in Figure 6B . We observed 106,063 and 89,793 high confidence peaks in 316 the Ascl1 control and Ascl1/STATi-treated samples, respectively ( Figure S3A ). The majority of 317 peaks overlapped between the two samples, with 80,169 sites being common to both treatment 318 conditions. Both datasets contained the canonical Ascl1 E-box as the top scoring motif, as 319 determined by HOMER, with strong central enrichment of peaks from both datasets around the 320 Ascl1 motif ( Figure S3B ).
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Based on our findings that inappropriate Ascl1 binding sites were frequently found with 322 the STAT motif, we hypothesized that inhibition of the STAT signal would reduce Ascl1 323 recruitment to these sites. To identify genes that might be regulated by STAT signaling in the 324 MG during reprogramming with Ascl1, we performed a differential analysis between the control 325 Ascl1 and Ascl1/STATi datasets using edgeR 37,38 . Individual peaks were compared between the 326 two datasets and plotted as a MA plot in Figure 6C . Ascl1 ChIP-seq peaks that were 327 significantly reduced in the STATi treatment condition ( Figure 6C , blue points) were present at 328 various STAT pathway target genes (e.g. Bcl2, Pias1, Stat5a/b), and Id1 and Id3 were among 329 these. Figure 6B shows decreased Ascl1 binding at STAT3 bound regions near Id1 and Id3 330 after STATi treatment, with gray highlights indicating the corresponding (significantly reduced) 331 peaks from Figure 6C . Together, these findings add further support to the hypothesis that STAT 332 signaling may redirect Ascl1 to non-productive cis-regulatory regions, and in some cases, 333 inhibitors of neural reprogramming, like Id1, Id3 and Hes5.
334
In addition to reducing the binding of Ascl1 to STAT target regions in MG, inhibition of 335 the STAT pathway leads to increases in Ascl1 binding to non-STAT targets. Ascl1 ChIP-seq 336 peaks that were significantly enriched in the STATi treatment condition ( Figure 6C , red points) 337 were present at neuronal genes associated with amacrine and bipolar cell fates (e.g. Elavl4, Otx2, Isl1, and Prox1) as well as synaptic genes (e.g. Dlg4 and Snap25), consistent with our 339 observations that this treatment leads to an increase in neuronal differentiation. By contrast, 340 peaks located near genes associated with progenitor cells were also significantly decreased in 341 the STATi treatment condition (e.g. Ccnd1 and Ccnd3). Thus, STATi results in enrichment of 342 Ascl1 binding at neuronal genes, suggesting that inhibiting STAT pathway activation during 343 reprogramming leads to more productive binding of Ascl1 at genes necessary for neurogenesis. 
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One potential target of STAT signaling that could limit the regenerative response in 385 mammalian MG is Id1. Following injury to the retina, the STAT target gene Id1 is transiently 386 expressed in MG, but Id1 returns to basal levels within a week. We found that in Ascl1-387 overexpressing mice, Id1 expression is maintained in the MG, possibly maintaining the cells in a 
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The HOMER software suite was used to determine and score peak calls ('findPeaks' function, 647 v4.7) as well as motif enrichment ('findMotifs' function, v4.7, using repeat mask). Peak overlap 648 analyses were performed using Bedops. Gene Ontology analyses of Ascl1 ChIP-seq peaks 649 were generated using GREAT algorithm. ChIP-seq datasets from Ascl1 and Ascl1/STATi conditions, and STAT3 ChIP-seq data from oligodendrocytes (GEO: GSM2650746). Gray highlights show peaks that were significantly decreased in STATi-treated cells. C) MA plot of all Ascl1 and Ascl1/STATi-treated Ascl1 ChIP-seq peaks. Red shows peaks that were significantly enriched in the STATitreated cells with a logFC >1 and blue shows peaks that were significantly decreased in the STATi-treated cells with a log FC <-1.
Figure 7 | Ascl1-overexpression results in dysregulated STAT-target genes. A)
Experimental paradigm for analyzing STAT-target genes in Ascl1-overexpressing MG. B) Both GFP-Sox2+ and Ascl1-expressing GFP+ MG express Id1 2 days after NMDA damage. C) Ascl1+ cells have higher expression of Id1 relative to GFP-MG (Sox2+ cells) 4 days after NMDA damage. D) Id1 expression is reduced in GFP-MG but remains in the Ascl1-expressing GFP+ MG 14 days after NMDA damage. Note, the flat Id1+ nuclei in all images not labelled with GFP are endothelial cells. Scale bars for B-D are 20 µm. E) Graph showing RT-qPCR for Id1 gene expression relative to WT on retinas treated 4 days post-NMDA. One-way ANOVA with Tukey's post-test; *P < 0.05, N = 4 biological replicates per condition run in triplicate. F) Id1 expression is reduced in GFP-MG but remains in the Ascl1-expressing GFP+ MG 14 days after ANT treatment (white arrows). MG-derived neurons (orange arrows) do not express Id1. Scale bar is 40 µm.
Figure S1 | STAT inhibitor SH-4-54 inhibits pSTAT3 in MG. A)
Experimental paradigm for analyzing STAT3 phosphorylation by western blot in MG. P11 retinas were dissociated and grown in a growth media containing mEGF for 7 DIV. MG were passaged to eliminate residual neurons and cultured in a media containing doxycycline to induce Ascl1 expression for 6 DIV. On the sixth day, the STATi SH-4-54 was added then cells were harvested 24 hours later for WB. B) Representative images from confluent cultures of non-treated, Doxtreated, and Dox + STATi-treated MG just before harvesting. C) Representative western blot for pSTAT3 (Y705), STAT3, and Beta-actin on non-treated, Dox-treated, and Dox+ STATi-treated MG cultures. D) Graph showing quantification of western blot bands was significantly different by One-way ANOVA with Tukey's posttest, *P < 0.05, ***P < 0.0001. E) Representative image of WT retinas injected with either PBS, NMDA, or SH-4-54 and collected 24 hours later for TUNEL staining. Scale bars for B and E are 25 and 40 µm, respectively. 
